Company profile: Therapeutic Solutions International
1.1 - Company Overview
Company description
- Provider of biotechnology therapies and nutraceuticals, including JadiCell mesenchymal stem cell therapy for COVID-19 lung injury, COPD, and CTE; QuadraMune to enhance natural killer cell activity and immune support; StemVacs and StemVacs-V cancer immunotherapies; CampbellCell for psychiatric diseases; and FloraStilbene as an immunotherapy adjuvant.
Products and services
- StemVacs: Dendritic cell-based immunotherapy that stimulates immune responses against cancer, targeting advanced solid tumors and metastatic breast cancer
- JadiCell: Mesenchymal stem cell therapy used to treat COVID-19–induced lung injury, chronic obstructive pulmonary disease, and chronic traumatic encephalopathy
- QuadraMune: Nutraceutical engineered to enhance natural killer cell activity and deliver immune support, particularly in the context of viral infections like COVID-19
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Therapeutic Solutions International
Lumicell
HQ: United States
Website
- Description: Provider of image-guided cancer surgery solutions, including the Lumicell Direct Visualization System (DVS), a fluorescence-guided imaging system that detects residual cancerous tissue in real time during lumpectomy, and LUMISIGHT (pegulicianine), an optical imaging agent used with DVS to highlight cancerous tissue during lumpectomy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumicell company profile →
Oncocyte
HQ: United States
Website
- Description: Provider of blood-based and gene expression tests and biopharma services: DetermaCNI detects cancer progression early via cell-free DNA instability; DetermaIO assesses the tumor immune microenvironment to identify immunotherapy benefit; VitaGraft Kidney/Liver quantify donor-derived cell-free DNA to monitor transplant health and detect rejection; GraftAssure uses droplet digital PCR; and tissue- and blood-based biomarker-driven clinical trial support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncocyte company profile →
Northwest Biotherapeutics
HQ: United States
Website
- Description: Provider of cancer immunotherapy products, focused on developing and commercializing personalized vaccine candidates: DCVax-L for newly diagnosed glioblastoma multiforme (GBM) in a Phase III trial; DCVax-Direct for direct injection into inoperable solid tumors in a Phase I/II trial; and DCVax-Prostate targeting late-stage, hormone-independent prostate cancer using a proprietary PSMA antigen.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Northwest Biotherapeutics company profile →
BioNovion
HQ: United States
Website
- Description: Provider of immune oncology antibody discovery and development focused on antibodies for the immune therapy of cancer; U.S.-based, founded in 2011 and acquired by Aduro BioTech in 2015.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioNovion company profile →
Checkpoint Therapeutics
HQ: United States
Website
- Description: Provider of immuno-oncology and targeted oncology therapies in development, advancing a pipeline including cosibelimab (fully human anti-PD-L1 monoclonal antibody), olafertinib (oral third-generation irreversible EGFR inhibitor for NSCLC), CK-103 (BET bromodomain inhibitor), CK-302 (agonistic GITR antibody), and an anti-CAIX antibody for renal cell carcinoma, plus product purchases, in-licensing and co-development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Checkpoint Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Therapeutic Solutions International
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Therapeutic Solutions International
2.2 - Growth funds investing in similar companies to Therapeutic Solutions International
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Therapeutic Solutions International
4.2 - Public trading comparable groups for Therapeutic Solutions International
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →